title: Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery.
abstract: A small library of novel 3-O-pegylated carboxylate prodrugs (4a-4b) and 3-O-pegylated carbamate prodrugs (9a-9b) of naltrexone were synthesized. The goal behind the design of these prodrugs was to investigate their potential for microneedle-enhanced transdermal delivery. All the synthesized 3-O-pegylated carboxylate prodrugs (4a-4b) and 3-O-pegylated carbamate prodrugs (9a-9b) of naltrexone were found to have adequate stability in a transdermal formulation and improved apparent solubility compared to naltrexone. Viscosity effects were postulated to be responsible for the observed non-linearity in the flux-concentration profile of these prodrugs.
authors.affiliation: Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA.
authors.forename: Thirupathi Reddy
authors.initials: TR
authors.lastname: Yerramreddy
authors.forename: Mikolaj
authors.initials: M
authors.lastname: Milewski
authors.forename: Narsimha Reddy
authors.initials: NR
authors.lastname: Penthala
authors.forename: Audra L
authors.initials: AL
authors.lastname: Stinchcomb
authors.forename: Peter A
authors.initials: PA
authors.lastname: Crooks
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D002264:Carboxylic Acids / Q000737:chemistry*; D009271:Naltrexone / Q000008:administration & dosage* / Q000737:chemistry; D009292:Narcotic Antagonists / Q000008:administration & dosage* / Q000737:chemistry; D009339:Needles; D011355:Prodrugs / Q000008:administration & dosage*; D012995:Solubility; D013552:Swine; D013556:Swine, Miniature; D014783:Viscosity
chemical_list: D002264:Carboxylic Acids; D009292:Narcotic Antagonists; D011355:Prodrugs; D009271:Naltrexone
references.citation: Pharm Res. 2005 May;22(5):758-65
references.pmid: 15906171
references.citation: Expert Opin Drug Deliv. 2009 Apr;6(4):343-54
references.pmid: 19348604
references.citation: Nat Biotechnol. 2008 Nov;26(11):1261-8
references.pmid: 18997767
references.citation: J Subst Abuse Treat. 2002 Dec;23(4):351-60
references.pmid: 12495797
references.citation: J Pharm Sci. 2005 Apr;94(4):828-36
references.pmid: 15736197
references.citation: Molecules. 2009 Oct 22;14(10):4231-45
references.pmid: 19924060
references.citation: Curr Drug Deliv. 2007 Jan;4(1):69-76
references.pmid: 17269919
references.citation: Neuropsychopharmacology. 2000 May;22(5):493-503
references.pmid: 10731624
references.citation: Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2058-63
references.pmid: 18250310
references.citation: Arch Gen Psychiatry. 1992 Nov;49(11):876-80
references.pmid: 1345133
references.citation: J Pharm Sci. 2010 Jul;99(7):3072-80
references.pmid: 20166200
references.citation: Pharm Res. 2004 Jul;21(7):1146-52
references.pmid: 15290853
references.citation: J Pharm Pharmacol. 2009 Jun;61(6):721-31
references.pmid: 19505362
references.citation: Nat Rev Drug Discov. 2003 Mar;2(3):214-21
references.pmid: 12612647
references.citation: J Control Release. 2005 Feb 2;102(2):509-20
references.pmid: 15653167
references.citation: Pharm Res. 2001 Dec;18(12):1789-93
references.pmid: 11785702
references.citation: Arch Gen Psychiatry. 1997 Aug;54(8):737-42
references.pmid: 9283509
references.citation: Eur J Pharm Biopharm. 2008 Aug;69(3):1040-5
references.pmid: 18411045
references.citation: J Pharm Sci. 1998 Aug;87(8):922-5
references.pmid: 9687334
references.citation: Drug Discov Today. 2005 Nov 1;10(21):1451-8
references.pmid: 16243265
references.citation: Pharm Res. 2008 Jan;25(1):104-13
references.pmid: 17597381
references.citation: Eur J Pharm Sci. 2001 Sep;14(2):123-34
references.pmid: 11500258
references.citation: Curr Opin Chem Biol. 1998 Aug;2(4):541-7
references.pmid: 9736929
references.citation: Pharm Res. 2008 Jul;25(7):1677-85
references.pmid: 18449628